Notice ID: 20bc8e27870c483b89389f5392ddcd68SolicitationArchived
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3
Archived on August 28, 2026. Original response deadline: . Full description on SAM.gov.
Overview
- Response deadline
- 9:00 AM EDT
- Posted
- July 2, 2026
- Notice type
- Solicitation
- NAICS
- 541714: Research and Development in Biotechnology (except Nanobiotechnology)
- Agency
- Department of WarDEFENSE ADVANCED RESEARCH PROJECTS AGENCY (DARPA)
Notice details
- Office
- DEF ADVANCED RESEARCH PROJECTS AGCY
- Last updated
- Oct 28, 2026
- First published
- Last updated on SAM.gov
Identifiers
- Solicitation number
- DARPA-PA-26-09
- Notice ID
- 20bc8e27870c483b89389f5392ddcd68
Description
Please note that this announcement specifically solicits proposals only for Task Area 3 (TA-3) of the RAPIID program.
Primary challenges with translating technological advancements from the laboratory to real-world usage include a lack of investment to ensure manufacturing scalability, and usability, as well as clinical, regulatory, and commercialization preparedness. Previous investments by DARPA to address potential blood shortages in austere, pre-hospital settings (i.e., the Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program) have derisked scalable, shelf-stable components that would provide the resuscitative functions of whole blood (i.e., oxygen delivery, hemostasis, and volume expansion) when used together. However, bringing those components through clinical studies and regulatory approval as well as the development of enabling technologies and guidance to facilitate their use outside of the laboratory were out-of-scope in previous DARPA efforts. RAPIID is designed to bridge the gap between the proof-of-concept achievements of the FSHARP program and actual clinical use by the military and civilians. With FSHARP demonstrating that shelf-stable blood products can be created, DARPA is now taking on the next challenge: delivering a complete, deployable, and authorized system that can save lives in the field. To achieve this goal, RAPIID will focus on pushing high technology readiness level (TRL)/medical readiness level (MRL) capabilities through the regulatory process by funding studies to demonstrate safety and efficacy of blood analog components and their ability to work in combination; manufacturing scalability of individual blood analog components; and developing and scaling associated fielding technologies.
Primary challenges with translating technological advancements from the laboratory to real-world usage include a lack of investment to ensure manufacturing scalability, and usability, as well as clinical, regulatory, and commercialization preparedness. Previous investments by DARPA to address potential blood shortages in austere, pre-hospital settings (i.e., the Fieldable Solutions for Hemorrhage with bio-Artificial Resuscitation Products (FSHARP) program) have derisked scalable, shelf-stable components that would provide the resuscitative functions of whole blood (i.e., oxygen delivery, hemostasis, and volume expansion) when used together. However, bringing those components through clinical studies and regulatory approval as well as the development of enabling technologies and guidance to facilitate their use outside of the laboratory were out-of-scope in previous DARPA efforts. RAPIID is designed to bridge the gap between the proof-of-concept achievements of the FSHARP program and actual clinical use by the military and civilians. With FSHARP demonstrating that shelf-stable blood products can be created, DARPA is now taking on the next challenge: delivering a complete, deployable, and authorized system that can save lives in the field. To achieve this goal, RAPIID will focus on pushing high technology readiness level (TRL)/medical readiness level (MRL) capabilities through the regulatory process by funding studies to demonstrate safety and efficacy of blood analog components and their ability to work in combination; manufacturing scalability of individual blood analog components; and developing and scaling associated fielding technologies.
Award Overview
No prior contract identified
No prior award matched this notice's agency, NAICS, place of performance and PSC within 18 months. It may be a new requirement.
Contacts
Contracting Officer
Primary Contact
LCDR Robert Murray, Program Manager, DARPA/BTO
Documents
Files (8)
- Download
DARPA-PA-26-09.pdf
1.5 MBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_F_Schedule_of_Milestones_and_Payments.xlsx
25 KBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_E_Task_Description_Document.docx
37 KBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_D_Sample_OT_R_.docx
152 KBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_B_Cost_Proposal.docx
58 KBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_A_Technical_Management_Proposal.docx
64 KBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_G_RAPIID_CUI_Guide.pdf
281 KBAdded in Solicitation version 3Posted - Download
RAPIID_TA3_Attachment_C_DARPA_Standard_Cost_Proposal_Spreadsheet.xlsx
364 KBAdded in Solicitation version 3Posted
Lifecycle
- 3Version 3SolicitationArchivedCurrent
Resuscitation and Prevention of Ischemia-Induced Dysfunction (RAPIID) - TA3
Similar Opportunities
Title | Match | Phase | Deadline |
|---|---|---|---|
Additional Details
Solicitation Number
DARPA-PA-26-09
Archive Date
Aug 28, 2026
Office Address
ARLINGTON, VA, 222032114